drugset / Trial / NCT00984464

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

NCT00984464

Phase 2 Completed 14 enrolled Oncolytics Biotech University of Texas · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.

Timeline

Start
2009-09
Primary completion
2014-02
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pelareorep Other / unclassified 3e+10 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous

Indications